Interventional Oncology Market: Growth, Size, Share, and Trends

Report Code MD 6975
Published in Jan, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Interventional Oncology Market by Devices & Consumables (RF, microwave, cryoablation. embolization), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung), End User (Hospital, Specialty Clinic) - Global Forecast to 2029

Overview

The global interventional oncology market, valued at US$2.53 billion in 2023, is forecasted to grow at a robust CAGR of 9.0%, reaching US$2.75 billion in 2024 and an impressive US$4.24 billion by 2029. The growth of the interventional oncology market is driven by several key factors, including the rising global burden of cancer, increasing demand for minimally invasive treatment options, and continuous technological advancements. Advances in the incidence of cancers of the liver, lungs, kidneys, and colon have been developing with many of these holding poor resectability, thereby indicating the increasing number of procedures in interventional oncology like transarterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), or percutaneous ablation. These methods provide targeted destruction of tumors with less systemic toxicity, faster recovery times, and fewer complications than do conventional surgical and chemotherapeutic modalities. In addition to this, greater preference for out-patient or day-care procedure due to higher cost-effectiveness and convenience will further add in the acceptance.

Interventional Oncology Market

Attractive Opportunities in the Interventional Oncology Market

Asia Pacific

The interventional oncology market in the Asia Pacific region is experiencing rapid growth, primarily owing to the surging prevalence of cancer and increasing geriatric population. Moreover, progress in less invasive procedures, and the embracing of new technology are further encouraging market growth

Cancer is on the rise in the region, with contributing factors such as aging populations, lifestyle changes, and environmental influences. This surge in cancer incidence creates a need for more advanced treatment options, which is why interventional oncology procedures are in higher demand.

Increasing patient awareness of the benefits of minimally invasive oncology treatments, such as reduced recovery times and fewer side effects, has boosted the adoption of interventional oncology techniques.

The Asia Pacific market is expected to be worth USD 934.3 million by 2029, growing at CAGR of 10.8% during the forecast period.

With constant innovation in medical imaging, interventional radiology, and image-guided therapies, interventional oncology iis continuously becoming more effective and precise in the delivery of treatment.

Global Interventional Oncology Market Dynamics

DRIVER: Expansion of cancer patient population

Expansion in the patient population for cancer is an important growth driver in the interventional oncology market. In fact, due to multiple causes, including age, lifestyle factors, and increasing exposure to risk factors from environmental sources, the global incidence of cancer has increased steadily over time. The most common forms of cancers are those affecting the liver, lung, kidney, and colorectal regions; most of the cases are diagnosed at advance stages wherein conventional surgical interventions are either ineffective or cannot be applied. This increasing patient population is demanding more of minimally invasive, image-guided interventions by interventional oncologists, in providing potential palliative and curative options. Interventional oncology techniques include transarterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), and percutaneous ablation. These are of significant importance in the treatment of today's cancer, especially for patients with inoperable and metastatic tumors.

RESTRAINT: High cost of interventional oncology

The expensive equipment involved with such procedures as well as sophisticated tools form some of the essential limitations holding the growth of interventional oncology. In particular, some treatments involving the disease under this treatment procedure are more sophisticated; thus, for TACE, TARE, and percutaneous ablation, for example, involve Yttrium-90 and a wide array of specialized catheters and embolic agents coupled with imaging technology in top shape, adding greatly to its expensive costs due to production and upscaling and other means.In addition, the highly specialized interventional radiologists and auxiliary staff increase the costs of the procedure. Most medical facilities, particularly in developing regions, are understaffed due to budgeting issues and inability to raise finance for the setup required, resulting in limited accessibility to interventional oncology.

 

OPPORTUNITY: Emerging economies offer high growth potential

Emerging economies, therefore, are significant growth opportunities for the interventional oncology market due to rapidly developing infrastructures of healthcare, an upsurge in cancer prevalence, and an increased demand for complex medical treatments in countries like those in Asia-Pacific, Latin America, and the Middle East & Africa. The regions experience high investment in modernising their healthcare facilities and improving accessibility to up-to-date medical equipment and delicate technologies. With an increasingly aging population, changing lifestyles, and rising rates of obesity, smoking, and hepatitis infection, the burden of cancer in these regions has made increasing access to more effective and accessible cancer treatment a pressing need. Interventional oncology is positioned well to meet these health care challenges because it lacks the invasiveness of traditional surgical oncology, recovery time is reduced, and it costs less markets.

CHALLENGES: Dearth of well-trained and skilled radiologist and oncologist

The interventional oncology market is currently under pressure by the inadequacy of well-trained and skilled interventional radiologists and oncologists, which would limit the widespread use of advanced minimally invasive cancer treatments. Tumor ablation, TACE, and TARE are interventional oncology procedures that require extremely specialized expertise in image-guided techniques, catheter navigation, and precision targeting of tumors. High procedure complexity demands serious training, access to advanced image equipment, and profound knowledge in the biology of the tumor before it is realized optimally during treatment. Conversely, however, access to adequate populations remains lacking across developing and emergent markets and areas where accessing medical education still poses a hurdle. Even inside the best-health-care systems the increasing demand exceeds even the supply to deliver interventional oncology practice.

Global Interventional Oncology Market Ecosystem Analysis

Interventional Oncology Market
 

By devices & consumables, embolization devices to be largest segment during forecast period

Embolization devices are trends in the interventional oncology market since they are what is mainly behind the minimally invasive treatments offered for cancers, providing various benefits to conventional surgical interventions. The working principle of these devices is to cut off any blood supply to the tumors, thereby starving them of their oxygen and nutrients necessary for its growth. Because they have proven efficacy in the management of nonresectable cancers, particularly for liver cancer, embolization techniques, like TACE and radioembolization or SIRT, are gaining much more popularity. Advancements in embolic technologies also include the use of drug-eluting beads and radioactive microspheres to make the treatments more targeted and efficient. With an ever-increasing cancer burden around the world, growing awareness regarding minimally invasive therapies, and an increased trend towards outpatient care, the demand for embolization devices has surged rapidly.

By cancer type, liver cancer to be largest segment during forecast period

Liver cancer remains the biggest share of the market in interventional oncology due to the increase in prevalence, mortality, and the requirement for efficient and minimally invasive treatments. The most common form of liver cancer, hepatocellular carcinoma, has strong associations with risk factors like chronic hepatitis B and C, excessive alcohol consumption, and a growing incidence of non-alcoholic fatty liver disease. Interventional oncology embraces targeted approaches like transarterial chemoembolization, transarterial radioembolization, and percutaneous ablation that have been established to be beneficial in the treatment of unresectable liver cancer. These therapies are highly effective and provide a localized control of tumor with reduced systemic side effects when compared to the conventional chemotherapy that improves survival outcomes as compared to traditional chemotherapy.

By procedure, transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT) to be largest segment during forecast period

The largest share in the interventional oncology market is captured by transcatheter arterial radioembolization, also referred to as selective internal radiation therapy, due to its established success in the treatment of both primary and secondary liver cancers, which contribute to a considerable proportion of deaths related to cancer. This is the method where radioactive isotope-loaded microspheres, commonly Yttrium-90, are placed directly into the hepatic artery feeding the tumor. Localized radiation treatment gives an opportunity for the selective destruction of the tumor with the least exposure of systemic radiation to other healthy tissues. TARE gains acceptance due to its safe profile and better tolerance by the patients, as well as a reduced side effect profile compared to conventional chemotherapy and external radiation therapy. This is very useful for patients suffering with unresectable HCC and liver metastases of colorectal carcinoma where the treatment options are limited or less effective.

By end user, hospitals to be largest segment during forecast period

Hospitals hold the largest share in the interventional oncology market because of robust infrastructure, cutting-edge technology, and multidisciplinary expertise that are necessary to perform complex interventional procedures. Specialized and minimally invasive techniques such as transarterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), and tumor ablation require advanced imaging systems, catheterization labs, and skilled interventional radiologists. Ideally, these capabilities are best served by tertiary care hospitals and specialized cancer centers. Hospitals also provide comprehensive, end-to-end care encompassing diagnosis, treatment, post-procedure management, and long-term follow-up, which makes them very attractive to patients who seek integrated and holistic cancer care solutions.

North America accounted for the largest share of the Interventional Oncology market in 2023.

The interventional oncology market is dominated by North America due to the well-developed health care infrastructure in the region, widespread acceptance of advanced medical technologies, and rising cancer cases. The United States is the biggest market within this region due to the existence of a well-established network of cancer centers and hospitals with modern facilities for interventional radiology. The growing incidence of liver, lung, and kidney cancers-the main areas for interventional oncology-provides significant impetus for less invasive treatments such as TACE, TARE, and thermal ablation. That the healthcare sector will be augmented by interventions in the form of highly qualified professionals, such as interventional radiologists and oncologists, also adds to the growth momentum.

HIGHEST CAGR MARKET IN 2024-2029
US FASTEST GROWING MARKET IN THE REGION
Interventional Oncology Market

Recent Developments of Interventional Oncology Market

  • In December 2024, AngioDynamics, Inc, expanding cancer treatment options and improving patient quality of life, announced receiving U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation.
  • In December 2024, Siemens Healthineers and AP-HP signed a partnership to innovate healthcare. This agreement strengthens their collaboration in medical imaging, diagnostics, and advanced therapies to improve patient care and adapt to changes in the French healthcare system, aiming to co-develop new.
  • In November 2024, Boston announced entering into a definitive agreement to acquire Intera Oncology Inc., a privately held medical device company that provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine, a chemotherapy drug, both of which are approved by the U.S. Food and Drug Administration.
  • In September 2024, Varian, a Siemens Healthineers company, announced a 10-year agreement with Ballad Health, to bring advanced oncology treatment services to serve patients in rural communities across the Appalachian Highlands in Northeast Tennessee, Southwest Virginia, northwestern North Carolina, and southeastern Kentucky.
  • In November 2023, ProSense received regulatory approval in India from the Central Drugs Standard Control Organisation (CDSCO) based on updated regulatory requirements.
  • In May 2023, Varian, a Siemens Healthineers company, introduced the Isolis cryoprobe, a single use, disposable device designed for use with CryoCare systems to improve procedural efficiency and precision for cryoablation.

Key Market Players

Want to explore hidden markets that can drive new revenue in Interventional Oncology Market?

Scope of the Report

Report Metric Details
Market size available for years 2024-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD Million/Billion)
Segments covered Devices & Consumables, Cancer Type, Procedure, End User and Region
Geographies covered North America (US & Canada), Europe (Germany, the UK, France, Italy, Spain, and RoE), APAC (Japan, China, Australia, South Korea India, and the RoAPAC), LATAM (Brazil, Mexico, and RoLATAM), and MEA (GCC Countries, RoMEA)

Key Questions Addressed by the Report

What is the expected addressable market value of the Interventional oncology market over 5 years?
The poultry pharmaceuticals market is projected to reach USD 4.24 billion by 2029 from USD 2.75 billion in 2024, at a CAGR of 9.0% during the forecast period.
What are the key drivers for the Interventional oncology market?
The overall driving forces for the interventional oncology market are the increasing prevalence of cancer globally, which has led to a higher need for effective treatment options. Preference of minimally invasive procedures like TACE, radioembolization, and ablation techniques is another significant factor because they provide a lesser duration to recover, less complications occur, and patient outcome is enhanced against traditional surgery.
Which country/region occupies the largest share of the Interventional oncology market, globally?
The interventional oncology market is dominated by North America due to the well-developed health care infrastructure in the region, widespread acceptance of advanced medical technologies, and rising cancer cases. The United States is the biggest market within this region due to the existence of a well-established network of cancer centers and hospitals with modern facilities for interventional radiology.
What are the strategies adopted by the top market players to penetrate emerging regions?
The major players in the market use partnerships, expansions, distribution agreements, product launches, and product approvals as important growth tactics.
What are the main players present in this market?
The main vendors in the market are include Siemens Healthineers AG (Varian) (US), Medtronic (Ireland), Boston Scientific Corporation (US), Terumo Corporation (Japan), Merit Medical Systems (US), Johnson & Johnson MedTech (Ethicon) (US), Stryker (US), Teleflex Incorporated (US), AngioDynamics (US).

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Interventional Oncology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table Of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
38
RESEARCH METHODOLOGY
44
EXECUTIVE SUMMARY
60
PREMIUM INSIGHTS
65
MARKET OVERVIEW
69
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rising preference for minimally invasive procedures
    - Growing prevalence of cancer
    - Increasing public-private funding and government support for interventional oncology
    - Technological advancements in interventional oncology
    RESTRAINTS
    - High cost of interventional oncology
    - Unfavorable regulations
    OPPORTUNITIES
    - Emerging economies offer high-growth potential
    CHALLENGES
    - Dearth of well-trained and skilled radiologists and oncologists
    - Strong market position of alternative therapies
  • 5.3 INDUSTRY TRENDS
    INNOVATIONS IN IMAGING AND TREATMENT TECHNOLOGIES
    INCREASING ADOPTION OF MINIMALLY INVASIVE PROCEDURES
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Ablation technologies
    - Embolization technologies
    COMPLEMENTARY TECHNOLOGY
    - Laparoscopy
    - Diagnostic imaging
    ADJACENT TECHNOLOGY
    - Radiation therapy systems
    - Chemotherapy
  • 5.6 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.8 REGULATORY LANDSCAPE
    KEY REGULATORY BODIES AND GOVERNMENT AGENCIES
    KEY REGULATORY GUIDELINES
    - US
    - Canada
    - Europe
    - Asia Pacific
    - Brazil
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.10 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR INTERVENTIONAL ONCOLOGY, JANUARY 2014–DECEMBER 2024
  • 5.11 TRADE ANALYSIS
  • 5.12 PRICING ANALYSIS
    AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023
    AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023 (USD)
    AVERAGE SELLING PRICE TREND OF INTERVENTIONAL ONCOLOGY DEVICES, BY REGION, 2021–2023
  • 5.13 KEY CONFERENCES AND EVENTS, 2025–2026
  • 5.14 UNMET NEEDS AND END USER EXPECTATIONS
    UNMET NEEDS
  • 5.15 END USER EXPECTATIONS IN INTERVENTIONAL ONCOLOGY MARKET
  • 5.16 ECOSYSTEM
  • 5.17 CASE STUDIES
  • 5.18 SUPPLY CHAIN ANALYSIS
  • 5.19 ADJACENT MARKET ANALYSIS
  • 5.20 INTERVENTIONAL ONCOLOGY MARKET, INVESTMENT AND FUNDING SCENARIO, 2020–2023
  • 5.21 IMPACT OF GENERATIVE AI ON INTERVENTIONAL ONCOLOGY MARKET
INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES
107
  • 6.1 INTRODUCTION
  • 6.2 EMBOLIZATION DEVICES
    RADIOEMBOLIC AGENTS
    - Precision-targeted therapy for challenging liver cancers to boost market
    NON-RADIOACTIVE EMBOLIC AGENTS
    - Non-radiation emitting agents to propel market
    - Microspheres
    - Coated beads
    - Microparticles
  • 6.3 ABLATION DEVICES
    RADIOFREQUENCY (RF) ABLATION DEVICES
    - Effective treatment of small or difficult-to-reach tumors to propel market growth
    MICROWAVE ABLATION DEVICES
    - Simultaneous treatment of multiple lesions to drive market growth
    CRYOABLATION DEVICES
    - Least painful and higher patient compatibility to drive market
    OTHER ABLATION DEVICES
  • 6.4 SUPPORT DEVICES
    MICROCATHETERS
    - Precise delivery of therapeutic agents to tumors to boost market
    GUIDEWIRES
    - Advancements in guidewire construction and launch of new and advanced products to propel market
    OTHER SUPPORT DEVICES
INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE
154
  • 7.1 INTRODUCTION
  • 7.2 LIVER CANCER
    INCREASING DISEASE PREVALENCE AND RISING RESEARCH ACTIVITIES TO DRIVE MARKET GROWTH
  • 7.3 KIDNEY CANCER
    FIRST-LINE THERAPY PRESERVING MORE KIDNEY TISSUE THAN SURGERY TO BOOST MARKET
  • 7.4 BREAST CANCER
    HIGH PRECISION, BETTER COSMETIC OUTCOMES, COST-EFFECTIVENESS, AND GREATER PATIENT COMFORT TO PROPEL MARKET
  • 7.5 LUNG CANCER
    INCREASING NUMBER OF CANCER CASES TO DRIVE DEMAND
  • 7.6 BONE CANCER
    DIRECT ELIMINATION OF TUMORS AND PAIN RELIEF TO FUEL MARKET
  • 7.7 PROSTATE CANCER
    RISING INCIDENCE OF PROSTATE CANCER AND GROWING ADOPTION OF METAL-BASED FIDUCIAL MARKERS TO CONTRIBUTE TO MARKET GROWTH
  • 7.8 OTHER CANCER TYPES
INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE
177
  • 8.1 INTRODUCTION
  • 8.2 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT)
    GREATER CLINICAL EFFICACY TO DRIVE MARKET GROWTH
  • 8.3 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE)
    ABILITY TO TREAT SMALL AND LARGE-SIZED TUMORS TO DRIVE DEMAND
  • 8.4 TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE)
    INCREASING CLINICAL EVIDENCE IN FAVOR OF TARE AND TACE TO RESTRAIN MARKET GROWTH
  • 8.5 THERMAL TUMOR ABLATION
    GROWING CLINICAL EVIDENCE PROVING EFFICACY OF TREATMENT OF VARIOUS TYPES OF CANCERS TO DRIVE MARKET GROWTH
  • 8.6 NON-THERMAL TUMOR ABLATION
    POTENTIAL ALTERNATIVE TO THERMAL TUMOR ABLATION TO BOOST MARKET
INTERVENTIONAL ONCOLOGY MARKET, BY END USER
194
  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS
    INCREASING NUMBER OF SURGERIES IN IN-PATIENT SETTINGS TO SUPPORT MARKET GROWTH
  • 9.3 SPECIALTY CLINICS
    INCREASING NUMBER OF CANCER CENTERS TO DRIVE MARKET GROWTH
  • 9.4 RESEARCH & ACADEMIC INSTITUTES
    COLLABORATIONS AMONG DEVICE MANUFACTURERS AND SUPPLIERS TO FUEL MARKET
INTERVENTIONAL ONCOLOGY MARKET, BY REGION
205
  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Rising cancer cases and preference for ablation procedures to boost market
    CANADA
    - Significant rise in cancer cases to drive market growth
  • 10.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Increase in incidence of cancer and rising geriatric population to fuel market
    UK
    - Increasing awareness and support for cancer-related activities to drive market
    FRANCE
    - Growing geriatric population to support market growth
    SPAIN
    - Increasing government funding for research to support market growth
    ITALY
    - Growing awareness about cancer and treatment options to support market growth
    REST OF EUROPE
  • 10.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    JAPAN
    - Rising geriatric population and universal healthcare reimbursement to drive market
    CHINA
    - Increasing incidence of cancer to drive market
    INDIA
    - Improving research capabilities and expansion of key players to drive market growth
    AUSTRALIA
    - Rising investments in research and awareness campaigns to support market growth
    SOUTH KOREA
    - Rising R&D and promising clinical trials to positively impact market growth
    REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Rising incidence of cancer and improving healthcare infrastructure to fuel market
    MEXICO
    - Increasing awareness campaigns and rising incidence of cancer to drive market growth
    REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK
    GCC COUNTRIES
    - Broader healthcare modernization initiatives in interventional oncology to drive market
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
376
  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2024
  • 11.3 REVENUE ANALYSIS, 2019−2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Region footprint
    - Devices & Consumables footprint
    - Cancer type footprint
    - Procedure footprint
    - End user footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    RESPONSIVE COMPANIES
    COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2023
    - Detailed list of key startups/SMES, 2023
    - Competitive benchmarking of key startups/SMEs
  • 11.7 VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 11.8 BRAND COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    PRODUCT & SERVICE LAUNCHES AND APPROVALS
    DEALS
    EXPANSIONS
COMPANY PROFILES
399
  • 12.1 KEY PLAYERS
    SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC)
    - Business overview
    - Products/Solutions/Services offered
    - Recent developments
    - MnM view
    BOSTON SCIENTIFIC CORPORATION
    - Business overview
    - Products/Solutions/Services offered
    - Recent developments
    - MnM view
    MEDTRONIC
    - Business overview
    - Products/Solutions/Services offered
    - MnM view
    TERUMO CORPORATION
    - Business overview
    - Products/Solutions/Services offered
    - Recent developments
    - MnM view
    MERIT MEDICAL SYSTEMS
    - Business overview
    - Products/Solutions/Services offered
    - Recent developments
    - MnM view
    JOHNSON & JOHNSON MEDTECH (ETHICON)
    - Business overview
    - Products/Solutions/Services offered
    TELEFLEX INCORPORATED
    - Business overview
    - Products/Solutions/Services offered
    ANGIODYNAMICS
    - Business overview
    - Products/Solutions/Services offered
    - Recent developments
    STRYKER
    - Business overview
    - Products/Solutions/Services offered
    IMBIOTECHNOLOGIES LTD.
    - Business overview
    - Products/Solutions/Services offered
    COOK
    - Business overview
    - Products/Solutions/Services offered
    ICECURE MEDICAL
    - Business overview
    - Products/Solutions/Services offered
    - Recent developments
    MEDWAVES, INC.
    - Business overview
    - Products/Solutions/Services offered
    PROFOUND MEDICAL
    - Business overview
    - Products/Solutions/Services offered
    RF MEDICAL CO., LTD.
    - Business overview
    - Products/Solutions/Services offered
    MINIMAX MEDICAL LIMITED
    - Business overview
    - Products/Solutions/Services offered
    ABK BIOMEDICAL INC.
    - Business overview
    - Products/Solutions/Services offered
    OLYMPUS CORPORATION
    - Business overview
    - Products/Solutions/Services offered
    SURGNOVA
    - Business overview
    - Products/Solutions/Services offered
    STARMED AMERICA
    - Business overview
    - Products/Solutions/Services offered
  • 12.2 OTHER PLAYERS
    SIRTEX SIR-SPHERES PTY LTD.
    GUERBET
    ACCURAY INCORPORATED
    EMBOLX, INC.
    SONABLATE CORP.
APPENDIX
448
  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 STANDARD CURRENCY CONVERSION RATES
  • TABLE 2 RISK ASSESSMENT: INTERVENTIONAL ONCOLOGY MARKET
  • TABLE 3 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
  • TABLE 4 KEY BUYING CRITERIA FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
  • TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 6 EUROPE: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 7 ASIA PACIFIC: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 8 LATIN AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 9 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 11 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 12 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 13 JAPAN: PMDA CLASSIFICATION OF ABLATION DEVICES
  • TABLE 14 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
  • TABLE 15 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 16 INDIA: CDSCO CLASSIFICATION OF ABLATION DEVICES
  • TABLE 17 LIST OF PATENTS IN INTERVENTIONAL ONCOLOGY MARKET, 2021–2024
  • TABLE 18 IMPORT DATA FOR INTERVENTIONAL ONCOLOGY (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND)
  • TABLE 19 EXPORT DATA FOR INTERVENTIONAL ONCOLOGY (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND)
  • TABLE 20 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023 (USD)
  • TABLE 21 AVERAGE SELLING PRICE TREND OF INTERVENTIONAL ONCOLOGY DEVICES, BY REGION, 2021–2023
  • TABLE 22 INTERVENTIONAL ONCOLOGY MARKET: KEY CONFERENCES & EVENTS, 2025–2026
  • TABLE 23 END USER EXPECTATIONS FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
  • TABLE 24 INTERVENTIONAL ONCOLOGY MARKET: ECOSYSTEM ANALYSIS
  • TABLE 25 TREATMENT OF HEPATOCELLULAR CARCINOMA WITH ARTERIOPORTAL SHUNTING USING BALLOON-ASSISTED TRANSARTERIAL YTTRIUM-90 RADIATION SEGMENTECTOMY
  • TABLE 26 RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY
  • TABLE 27 UPPER POLE ANGIOMYOLIPOMA (AML) EMBOLIZATION
  • TABLE 28 INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 29 INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 30 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 31 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 32 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 33 INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 34 RADIOEMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS
  • TABLE 35 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOEMBOLIC AGENTS, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 36 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOEMBOLIC AGENTS, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 37 NON-RADIOACTIVE EMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS
  • TABLE 38 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 39 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 40 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 41 INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 42 INTERVENTIONAL ONCOLOGY MARKET FOR MICROSPHERES, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 43 INTERVENTIONAL ONCOLOGY MARKET FOR MICROSPHERES, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 44 INTERVENTIONAL ONCOLOGY MARKET FOR COATED BEADS, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 45 INTERVENTIONAL ONCOLOGY MARKET FOR COATED BEADS, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 46 MAJOR BRANDS OF MICROCARRIERS
  • TABLE 47 INTERVENTIONAL ONCOLOGY MARKET FOR MICROPARTICLES, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 48 INTERVENTIONAL ONCOLOGY MARKET FOR MICROPARTICLES, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 49 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 50 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 51 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 52 INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 53 RADIOFREQUENCY ABLATION DEVICES OFFERED BY MAJOR MARKET PLAYERS
  • TABLE 54 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOFREQUENCY ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 55 INTERVENTIONAL ONCOLOGY MARKET FOR RADIOFREQUENCY ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 56 RADIOFREQUENCY ABLATION SYSTEMS, BY REGION, 2023–2029 (THOUSAND UNITS)
  • TABLE 57 INTERVENTIONAL ONCOLOGY MARKET FOR MICROWAVE ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 58 INTERVENTIONAL ONCOLOGY MARKET FOR MICROWAVE ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 59 MICROWAVE ABLATION SYSTEMS, BY REGION, 2023–2029 (THOUSAND UNITS)
  • TABLE 60 INTERVENTIONAL ONCOLOGY MARKET FOR CRYOABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 61 INTERVENTIONAL ONCOLOGY MARKET FOR CRYOABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 62 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 63 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 64 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 65 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 66 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 67 INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 68 INTERVENTIONAL ONCOLOGY MARKET FOR MICROCATHETERS, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 69 INTERVENTIONAL ONCOLOGY MARKET FOR MICROCATHETERS, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 70 INTERVENTIONAL ONCOLOGY MARKET FOR GUIDEWIRES, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 71 INTERVENTIONAL ONCOLOGY MARKET FOR GUIDEWIRES, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 72 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER SUPPORT DEVICES, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 73 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER SUPPORT DEVICES, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 74 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 75 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 76 INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 77 INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 78 INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 79 INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 80 INTERVENTIONAL ONCOLOGY MARKET FOR BREAST CANCER, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 81 INTERVENTIONAL ONCOLOGY MARKET FOR BREAST CANCER, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 82 INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 83 INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 84 INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 85 INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 86 INTERVENTIONAL ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 87 INTERVENTIONAL ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 88 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 89 INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 90 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 91 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 92 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT), BY REGION, 2019–2023 (USD MILLION)
  • TABLE 93 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT), BY REGION, 2024–2029 (USD MILLION)
  • TABLE 94 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE), BY REGION, 2019–2023 (USD MILLION)
  • TABLE 95 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE), BY REGION, 2024–2029 (USD MILLION)
  • TABLE 96 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE), BY REGION, 2019–2023 (USD MILLION)
  • TABLE 97 INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE), BY REGION, 2024–2029 (USD MILLION)
  • TABLE 98 INTERVENTIONAL ONCOLOGY MARKET FOR THERMAL TUMOR ABLATION, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 99 INTERVENTIONAL ONCOLOGY MARKET FOR THERMAL TUMOR ABLATION, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 100 INTERVENTIONAL ONCOLOGY MARKET FOR NON-THERMAL TUMOR ABLATION, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 101 INTERVENTIONAL ONCOLOGY MARKET FOR NON-THERMAL TUMOR ABLATION, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 102 INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 103 INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 104 INTERVENTIONAL ONCOLOGY MARKET FOR HOSPITALS, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 105 INTERVENTIONAL ONCOLOGY MARKET FOR HOSPITALS, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 106 INTERVENTIONAL ONCOLOGY MARKET FOR SPECIALTY CLINICS, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 107 INTERVENTIONAL ONCOLOGY MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 108 INTERVENTIONAL ONCOLOGY MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 109 INTERVENTIONAL ONCOLOGY MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 110 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2019–2023 (USD MILLION)
  • TABLE 111 INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2024–2029 (USD MILLION)
  • TABLE 112 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 113 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION)
  • TABLE 114 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 115 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 116 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 117 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 118 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 119 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 120 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 121 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 122 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 123 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 124 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 125 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 126 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 127 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 128 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 129 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 130 US: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 131 US: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 132 US: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 133 US: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 134 US: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 135 US: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 136 US: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 137 US: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 138 US: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 139 US: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 140 US: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 141 US: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 142 US: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 143 US: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 144 US: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 145 US: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 146 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 147 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 148 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 149 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 150 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 151 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 152 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 153 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 154 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 155 CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 156 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 157 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 158 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 159 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 160 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 161 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 162 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 163 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION)
  • TABLE 164 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 165 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 166 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 167 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 168 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 169 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 170 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 171 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 172 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 173 EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 174 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 175 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 176 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 177 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 178 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 179 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 180 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 181 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 182 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 183 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 184 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 185 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 186 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 187 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 188 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 189 GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 190 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 191 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 192 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 193 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 194 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 195 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 196 UK: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 197 UK: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 198 UK: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 199 UK: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 200 UK: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 201 UK: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 202 UK: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 203 UK: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 204 UK: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 205 UK: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 206 UK: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 207 UK: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 208 UK: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 209 UK: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 210 UK: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 211 UK: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 212 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 213 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 214 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 215 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 216 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 217 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 218 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 219 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 220 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 221 FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 222 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 223 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 224 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 225 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 226 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 227 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 228 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 229 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 230 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 231 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 232 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 233 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 234 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 235 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 236 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 237 SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 238 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 239 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 240 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 241 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 242 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 243 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 244 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 245 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 246 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 247 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 248 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 249 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 250 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 251 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 252 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 253 ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 254 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 255 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 256 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 257 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 258 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 259 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 260 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 261 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 262 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 263 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 264 REST OF EUROPE INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 265 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 266 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 267 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 268 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 269 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 270 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 271 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 272 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 273 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 274 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 275 REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 276 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 277 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION)
  • TABLE 278 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 279 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 280 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 281 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 282 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 283 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 284 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 285 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 286 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 287 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 288 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 289 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 290 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 291 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 292 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 293 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 294 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 295 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 296 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 297 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 298 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 299 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 300 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 301 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 302 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 303 JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 304 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 305 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 306 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 307 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 308 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 309 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 310 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 311 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 312 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 313 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 314 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 315 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 316 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 317 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 318 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 319 CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 320 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 321 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 322 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 323 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 324 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 325 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 326 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 327 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 328 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 329 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 330 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 331 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 332 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 333 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 334 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 335 INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 336 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 337 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 338 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 339 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 340 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 341 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 342 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 343 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 344 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 345 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 346 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 347 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 348 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 349 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 350 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 351 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 352 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 353 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 354 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 355 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 356 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 357 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 358 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 359 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 360 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 361 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 362 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 363 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 364 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 365 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 366 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 367 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 368 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 369 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 370 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 371 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 372 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 373 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 374 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 375 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 376 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 377 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 378 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 379 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 380 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 381 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 382 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 383 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 384 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 385 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 386 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 387 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 388 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 389 REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 390 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 391 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION)
  • TABLE 392 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 393 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 394 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 395 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 396 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 397 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 398 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 399 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 400 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 401 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 402 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 403 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 404 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 405 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 406 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 407 LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 408 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 409 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 410 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 411 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 412 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 413 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 414 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 415 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 416 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 417 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 418 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 419 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 420 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 421 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 422 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 423 BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 424 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 425 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 426 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 427 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 428 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 429 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 430 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 431 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 432 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 433 MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 434 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 435 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 436 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 437 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 438 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 439 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 440 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 441 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 442 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 443 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 444 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 445 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 446 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 447 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 448 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 449 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 450 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 451 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 452 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 453 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 454 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 455 REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 456 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 457 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION)
  • TABLE 458 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 459 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 460 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 461 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 462 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 463 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 464 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 465 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 466 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 467 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 468 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 469 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 470 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 471 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 472 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 473 MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 474 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 475 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 476 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 477 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 478 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 479 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 480 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 481 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 482 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 483 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 484 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 485 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 486 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 487 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 488 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 489 GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 490 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)
  • TABLE 491 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)
  • TABLE 492 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 493 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 494 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 495 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 496 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 497 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 498 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)
  • TABLE 499 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)
  • TABLE 500 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)
  • TABLE 501 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)
  • TABLE 502 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)
  • TABLE 503 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)
  • TABLE 504 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)
  • TABLE 505 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)
  • TABLE 506 STRATEGIES ADOPTED BY KEY PLAYERS IN INTERVENTIONAL ONCOLOGY MARKET, JANUARY 2021–DECEMBER 2024
  • TABLE 507 INTERVENTIONAL ONCOLOGY MARKET: DEGREE OF COMPETITION
  • TABLE 508 INTERVENTIONAL ONCOLOGY MARKET: REGION FOOTPRINT
  • TABLE 509 INTERVENTIONAL ONCOLOGY MARKET: DEVICES & CONSUMABLES FOOTPRINT
  • TABLE 510 INTERVENTIONAL ONCOLOGY MARKET: CANCER TYPE FOOTPRINT
  • TABLE 511 INTERVENTIONAL ONCOLOGY MARKET: PROCEDURE FOOTPRINT
  • TABLE 512 INTERVENTIONAL ONCOLOGY MARKET: END USER FOOTPRINT
  • TABLE 513 INTERVENTIONAL ONCOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES, 2023
  • TABLE 514 INTERVENTIONAL ONCOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 515 INTERVENTIONAL ONCOLOGY MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 516 INTERVENTIONAL ONCOLOGY MARKET: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 517 INTERVENTIONAL ONCOLOGY MARKET: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 518 SIEMENS HEALTHINEERS AG (VARIAN): COMPANY OVERVIEW
  • TABLE 519 SIEMENS HEALTHINEERS AG (VARIAN): PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 520 SIEMENS HEALTHINEERS AG (VARIAN): PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 521 SIEMENS HEALTHINEERS AG (VARIAN): DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 522 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
  • TABLE 523 BOSTON SCIENTIFIC CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 524 BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 525 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 526 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 527 MEDTRONIC: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 528 TERUMO CORPORATION: COMPANY OVERVIEW
  • TABLE 529 TERUMO CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 530 TERUMO CORPORATION: EXPANSIONS, JANUARY 2021– DECEMBER 2024
  • TABLE 531 MERIT MEDICAL SYSTEMS: COMPANY OVERVIEW
  • TABLE 532 MERIT MEDICAL SYSTEMS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 533 MERIT MEDICAL SYSTEMS: EXPANSIONS, JANUARY 2021– DECEMBER 2024
  • TABLE 534 JOHNSON & JOHNSON MEDTECH (ETHICON): COMPANY OVERVIEW
  • TABLE 535 JOHNSON & JOHNSON MEDTECH (ETHICON): PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 536 TELEFLEX INCORPORATED: COMPANY OVERVIEW
  • TABLE 537 TELEFLEX INCORPORATED: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 538 ANGIODYNAMICS: COMPANY OVERVIEW
  • TABLE 539 ANGIODYNAMICS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 540 ANGIODYNAMICS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 541 STRYKER: COMPANY OVERVIEW
  • TABLE 542 STRYKER: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 543 IMBIOTECHNOLOGIES LTD.: COMPANY OVERVIEW
  • TABLE 544 IMBIOTECHNOLOGIES LTD.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 545 COOK: COMPANY OVERVIEW
  • TABLE 546 COOK: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 547 ICECURE MEDICAL: COMPANY OVERVIEW
  • TABLE 548 ICECURE MEDICAL: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 549 ICECURE MEDICAL LTD.: PRODUCT APPROVALS
  • TABLE 550 ICECURE MEDICAL LTD.: DEALS
  • TABLE 551 MEDWAVES, INC.: COMPANY OVERVIEW
  • TABLE 552 MEDWAVES INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 553 PROFOUND MEDICAL: COMPANY OVERVIEW
  • TABLE 554 PROFOUND MEDICAL: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 555 RF MEDICAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 556 RF MEDICAL CO., LTD.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 557 MINIMAX MEDICAL LIMITED: COMPANY OVERVIEW
  • TABLE 558 MINIMAX MEDICAL LIMITED: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 559 ABK BIOMEDICAL INC.: COMPANY OVERVIEW
  • TABLE 560 ABK BIOMEDICAL INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 561 OLYMPUS CORPORATION: COMPANY OVERVIEW
  • TABLE 562 OLYMPUS CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 563 SURGNOVA: COMPANY OVERVIEW
  • TABLE 564 SURGNOVA: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 565 STARMED AMERICA: COMPANY OVERVIEW
  • TABLE 566 STARMED AMERICA: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 567 SIRTEX SIR-SPHERES PTY LTD.: COMPANY OVERVIEW
  • TABLE 568 GUERBET: COMPANY OVERVIEW
  • TABLE 569 ACCURAY: COMPANY OVERVIEW
  • TABLE 570 EMBOLX, INC.: COMPANY OVERVIEW
  • TABLE 571 SONABLATE CORP.: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 INTERVENTIONAL ONCOLOGY MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF INTERVIEWS WITH EXPERTS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF INTERVIEWS WITH EXPERTS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6 BREAKDOWN OF INTERVIEWS WITH EXPERTS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
  • FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: SIEMENS HEALTHINEERS AG (2023)
  • FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: INTERVENTIONAL ONCOLOGY MARKET (2023)
  • FIGURE 10 TOP-DOWN APPROACH
  • FIGURE 11 ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029)
  • FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 13 DATA TRIANGULATION METHODOLOGY
  • FIGURE 14 EMBOLIZATION DEVICES SEGMENT TO DOMINATE INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD (USD MILLION)
  • FIGURE 15 LIVER CANCER TYPE SEGMENT TO LEAD MARKET DURING FORECAST PERIOD (USD MILLION)
  • FIGURE 16 THERMAL TUMOR ABLATION SEGMENT TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD (USD MILLION)
  • FIGURE 17 HOSPITALS SEGMENT TO DOMINATE INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD (USD MILLION)
  • FIGURE 18 NORTH AMERICA ACCOUNTED FOR LARGEST SHARE OF INTERVENTIONAL ONCOLOGY MARKET IN 2023
  • FIGURE 19 GROWING DEMAND FOR INTERVENTIONAL ONCOLOGY TO DRIVE MARKET
  • FIGURE 20 EMBOLIZATION DEVICES ACCOUNTED FOR LARGEST SHARE OF INTERVENTIONAL ONCOLOGY MARKET IN 2023
  • FIGURE 21 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 22 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
  • FIGURE 24 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN INTERVENTIONAL ONCOLOGY MARKET
  • FIGURE 25 VALUE CHAIN ANALYSIS: MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
  • FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
  • FIGURE 27 KEY BUYING CRITERIA FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
  • FIGURE 28 PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES
  • FIGURE 29 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES
  • FIGURE 30 EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES
  • FIGURE 31 REVENUE SHIFT IN INTERVENTIONAL ONCOLOGY MARKET
  • FIGURE 32 PATENT PUBLICATION TRENDS, JANUARY 2014–DECEMBER 2024
  • FIGURE 33 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR INTERVENTIONAL ONCOLOGY, JANUARY 2014–DECEMBER 2024
  • FIGURE 34 TOP APPLICANT JURISDICTIONS FOR INTERVENTIONAL ONCOLOGY PATENTS, JANUARY 2014–DECEMBER 2024
  • FIGURE 35 AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES, BY KEY PLAYER, 2023
  • FIGURE 36 END USER EXPECTATIONS IN EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES
  • FIGURE 37 INTERVENTIONAL ONCOLOGY MARKET: ECOSYSTEM
  • FIGURE 38 INTERVENTIONAL ONCOLOGY MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 39 ADJACENT MARKETS TO INTERVENTIONAL ONCOLOGY MARKET
  • FIGURE 40 INVESTMENT/VENTURE CAPITAL SCENARIO IN INTERVENTIONAL ONCOLOGY MARKET, 2020–2023
  • FIGURE 41 CHINA TO GROW AT HIGHEST CAGR IN INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD
  • FIGURE 42 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
  • FIGURE 43 EUROPE: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
  • FIGURE 44 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
  • FIGURE 45 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN INTERVENTIONAL ONCOLOGY MARKET,2019−2023
  • FIGURE 46 INTERVENTIONAL ONCOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2023
  • FIGURE 47 INTERVENTIONAL ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 48 INTERVENTIONAL ONCOLOGY MARKET: COMPANY FOOTPRINT
  • FIGURE 49 INTERVENTIONAL ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 50 EV/EBITDA OF KEY VENDORS
  • FIGURE 51 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 52 INTERVENTIONAL ONCOLOGY MARKET: COMPARATIVE BRAND ANALYSIS
  • FIGURE 53 SIEMENS HEALTHINEERS AG (VARIAN): COMPANY SNAPSHOT (2024)
  • FIGURE 54 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 55 MEDTRONIC: COMPANY SNAPSHOT (2024)
  • FIGURE 56 TERUMO CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 57 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT (2023)
  • FIGURE 58 JOHNSON & JOHNSON MEDTECH (ETHICON): COMPANY SNAPSHOT (2023)
  • FIGURE 59 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2023)
  • FIGURE 60 ANGIODYNAMICS: COMPANY SNAPSHOT (2024)
  • FIGURE 61 STRYKER: COMPANY SNAPSHOT (2023)
  • FIGURE 62 ICECURE MEDICAL LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 63 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2024)

The study involved four major activities to estimate the current size of the Interventional Oncology market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to to identify and collect information for the study of Interventional oncology market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

Extensive primary research was conducted after obtaining information regarding the Interventional oncology market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand and supply sides across major countries of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Primary data was collected through questionnaires, emails, and telephonic interviews. The primary sources from the supply side included various industry experts, such as Chief X Officers (CXOs), Vice Presidents (VPs), Directors from business development, marketing, product development/innovation teams, and related key executives from manufacturers; distributors operating in the Interventional oncology market.; and key opinion leaders.

Primary interviews were conducted to gather insights such as market statistics, data on revenue collected from the products and services, market breakdowns, market size estimations, market forecasting, and data triangulation. Primary research also helped in understanding the various trends related to technology, application, vertical, and region. Stakeholders from the demand side customers/end users who are using infection control products were interviewed to understand the buyer’s perspective on the suppliers, products, and their current usage and the future outlook of their business, which will affect the overall market.

The following is a breakdown of the primary respondents:

Interventional Oncology Market

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.

Note 2: Other primaries include sales managers, marketing managers, and product managers.

Note 3: Companies are classified into tiers based on their total revenue.

As of 2023: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, Tier 3=< USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The research methodology used to estimate the size of the interventional oncology market includes the following details.

The market sizing of the market was undertaken from the global side.

Country-level Analysis: The size of the Interventional oncology market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products in the overall Interventional oncology market was obtained from secondary data and validated by primary participants to arrive at the total Interventional Oncology market. Primary participants further validated the numbers.

Geographic market assessment (by region & country): The geographic assessment was done using the following approaches:

Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends

Approach 2: Geographic adoption trends for individual devices & consumables segments by end users and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)

At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall Interventional oncology market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.

Global Interventional Oncology market Size: Bottom -Up Approach & Top – down approach

Interventional Oncology Market

Data Triangulation

The market was split into several segments and subsegments after arriving at the overall market size—using the market size estimation processes. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment. The data was triangulated by studying various factors and trends from both the demand and supply sides in the Interventional Oncology market.

Market Definition

Interventional Oncology is a type of cancer treatment that includes minimally invasive treatment procedures and associated products involving tumor ablation and embolization techniques which are supported by image guidance and sometimes a contrast agent. Interventional Oncology is an alternative to chemotherapy, radiation oncology, and surgical oncology offering target specific treatment of cancer with least damage caused to the surrounding healthy cells. Interventional oncology is widely considered as a sub-specialty of interventional radiology.

Stakeholders

  • Minimally invasive medical devices, ablation, and embolization product manufacturing companies
  • Distributors, suppliers, and commercial service providers
  • Healthcare service providers
  • Clinical Research Organizations (CROs)
  • Ablation and embolization service providers
  • Minimally invasive medical devices, ablation, and embolization product distributors
  • Medical research laboratories
  • Market research and consulting firms
  • Academic medical centers and universities
  • Cancer research organizations

Report Objectives

  • To define, describe, segment, and forecast the global Interventional Oncology market by types and region.
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets1 concerning individual growth trends, prospects, and contributions to the overall Interventional Oncology market.
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
  • To forecast the size of the Interventional Oncology market in five main regions along with their respective key countries, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players in the global Interventional Oncology market and comprehensively analyze their core competencies2 and market shares.
  • To track and analyze competitive developments such as acquisitions, expansions, partnerships, agreements, and collaborations; and product launches and approvals.
  • To benchmark players within the Interventional Oncology market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

Previous Versions of this Report

Interventional Oncology Market by Product (Radiofrequency, microwave, embolization, guidewires), Procedure (Thermal, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis), Enduser (Hospital, ASC) - Global Forecast to 2026

Report Code MD 6975
Published in May, 2021, By MarketsandMarkets™

Interventional Oncology Market by Product (Radiofrequency, microwave, embolization, guidewires), Procedure (Thermal, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis), Enduser (Hospital, ASC) - Global Forecast to 2026

Report Code MD 6975
Published in Mar, 2019, By MarketsandMarkets™

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Interventional Oncology Market

DMCA.com Protection Status